Serum hsa-miR-22-3p, hsa-miR-885-5p, Lipase-to-Amylase Ratio, C-Reactive Protein, CA19-9, and Neutrophil-to-Lymphocyte Ratio as Prognostic Factors in Advanced Pancreatic Ductal Adenocarcinoma
Pancreatic cancer (PC) is the seventh most common cause of cancer-related death worldwide. The low survival rate may be due to late diagnosis and asymptomatic early-stage disease. Most patients are diagnosed at an advanced stage of the disease. The search for novel prognostic factors is still needed...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-01-01
|
| Series: | Current Issues in Molecular Biology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1467-3045/47/1/27 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832588750202339328 |
|---|---|
| author | Jakub Wnuk Dorota Hudy Joanna Katarzyna Strzelczyk Łukasz Michalecki Kamil Dybek Iwona Gisterek-Grocholska |
| author_facet | Jakub Wnuk Dorota Hudy Joanna Katarzyna Strzelczyk Łukasz Michalecki Kamil Dybek Iwona Gisterek-Grocholska |
| author_sort | Jakub Wnuk |
| collection | DOAJ |
| description | Pancreatic cancer (PC) is the seventh most common cause of cancer-related death worldwide. The low survival rate may be due to late diagnosis and asymptomatic early-stage disease. Most patients are diagnosed at an advanced stage of the disease. The search for novel prognostic factors is still needed. Two miRNAs, miR-22-3p and miR-885-5p, which show increased expression in PC, were selected for this study. The aim of this study was to evaluate the utility of these miRNAs in the prognosis of PC. Other prognostic factors such as lipase-to-amylase ratio (LAR), neutrophil-to-lymphocyte ratio (NLR), and carbohydrate antigen 19-9 (CA19-9) were also evaluated in this study. This study was conducted in 50 patients previously diagnosed with pancreatic ductal adenocarcinoma in clinical stage (CS) III and IV. All patients underwent a complete medical history, physical examination, and routine laboratory tests including a complete blood count, C-reactive protein (CRP), CA19-9, lipase, and amylase. Two additional blood samples were taken from each patient to separate plasma and serum. Isolation of miRNA was performed using TRI reagent with cel-miR-39-3p as a spike-in control. Reverse transcription of miRNA was performed using a TaqMan Advanced miRNA cDNA Synthesis Kit. The relative expression levels of miR-22-3p and miR-885-5p were measured using RT-qPCR. Serum hsa-miR-22-3p was detected in 22 cases (44%), while hsa-miR-885-5p was detected in 33 cases (66%). There were no statistically significant differences in serum or plasma miRNA expression levels between patient groups based on clinical stage, gender, or BMI. There were no statistically significant differences in LAR between patients with different CS. For NLR, CRP and CA19-9 thresholds were determined using ROC analysis (6.63, 24.7 mg/L and 4691 U/mL, respectively). Cox’s F test for overall survival showed statistically significant differences between groups (<i>p</i> = 0.002 for NLR, <i>p</i> = 0.007 for CRP and <i>p</i> = 0.007 for CA19-9). Utility as prognostic biomarkers was confirmed in univariate and multivariate analysis for CA19-9, CRP, and NLR. The selected miRNAs and LAR were not confirmed as reliable prognostic markers in PC. |
| format | Article |
| id | doaj-art-26aa7fcb0fd74adb84409041f598d90e |
| institution | Kabale University |
| issn | 1467-3037 1467-3045 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Issues in Molecular Biology |
| spelling | doaj-art-26aa7fcb0fd74adb84409041f598d90e2025-01-24T13:27:26ZengMDPI AGCurrent Issues in Molecular Biology1467-30371467-30452025-01-014712710.3390/cimb47010027Serum hsa-miR-22-3p, hsa-miR-885-5p, Lipase-to-Amylase Ratio, C-Reactive Protein, CA19-9, and Neutrophil-to-Lymphocyte Ratio as Prognostic Factors in Advanced Pancreatic Ductal AdenocarcinomaJakub Wnuk0Dorota Hudy1Joanna Katarzyna Strzelczyk2Łukasz Michalecki3Kamil Dybek4Iwona Gisterek-Grocholska5Department of Oncology and Radiotherapy, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, 35 Ceglana St., 40-515 Katowice, PolandDepartment of Medical and Molecular Biology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, 19 Jordana St., 41-808 Zabrze, PolandDepartment of Medical and Molecular Biology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, 19 Jordana St., 41-808 Zabrze, PolandDepartment of Oncology and Radiotherapy, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, 35 Ceglana St., 40-515 Katowice, PolandCentral Laboratory, University Clinical Center, Medical University of Silesia in Katowice, 14 Medyków St., 40-752 Katowice, PolandDepartment of Oncology and Radiotherapy, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, 35 Ceglana St., 40-515 Katowice, PolandPancreatic cancer (PC) is the seventh most common cause of cancer-related death worldwide. The low survival rate may be due to late diagnosis and asymptomatic early-stage disease. Most patients are diagnosed at an advanced stage of the disease. The search for novel prognostic factors is still needed. Two miRNAs, miR-22-3p and miR-885-5p, which show increased expression in PC, were selected for this study. The aim of this study was to evaluate the utility of these miRNAs in the prognosis of PC. Other prognostic factors such as lipase-to-amylase ratio (LAR), neutrophil-to-lymphocyte ratio (NLR), and carbohydrate antigen 19-9 (CA19-9) were also evaluated in this study. This study was conducted in 50 patients previously diagnosed with pancreatic ductal adenocarcinoma in clinical stage (CS) III and IV. All patients underwent a complete medical history, physical examination, and routine laboratory tests including a complete blood count, C-reactive protein (CRP), CA19-9, lipase, and amylase. Two additional blood samples were taken from each patient to separate plasma and serum. Isolation of miRNA was performed using TRI reagent with cel-miR-39-3p as a spike-in control. Reverse transcription of miRNA was performed using a TaqMan Advanced miRNA cDNA Synthesis Kit. The relative expression levels of miR-22-3p and miR-885-5p were measured using RT-qPCR. Serum hsa-miR-22-3p was detected in 22 cases (44%), while hsa-miR-885-5p was detected in 33 cases (66%). There were no statistically significant differences in serum or plasma miRNA expression levels between patient groups based on clinical stage, gender, or BMI. There were no statistically significant differences in LAR between patients with different CS. For NLR, CRP and CA19-9 thresholds were determined using ROC analysis (6.63, 24.7 mg/L and 4691 U/mL, respectively). Cox’s F test for overall survival showed statistically significant differences between groups (<i>p</i> = 0.002 for NLR, <i>p</i> = 0.007 for CRP and <i>p</i> = 0.007 for CA19-9). Utility as prognostic biomarkers was confirmed in univariate and multivariate analysis for CA19-9, CRP, and NLR. The selected miRNAs and LAR were not confirmed as reliable prognostic markers in PC.https://www.mdpi.com/1467-3045/47/1/27circulating miRNAspancreatic ductal adenocarcinomaneutrophil–lymphocyte ratiolipase–amylase ratioCA19-9C-reactive protein |
| spellingShingle | Jakub Wnuk Dorota Hudy Joanna Katarzyna Strzelczyk Łukasz Michalecki Kamil Dybek Iwona Gisterek-Grocholska Serum hsa-miR-22-3p, hsa-miR-885-5p, Lipase-to-Amylase Ratio, C-Reactive Protein, CA19-9, and Neutrophil-to-Lymphocyte Ratio as Prognostic Factors in Advanced Pancreatic Ductal Adenocarcinoma Current Issues in Molecular Biology circulating miRNAs pancreatic ductal adenocarcinoma neutrophil–lymphocyte ratio lipase–amylase ratio CA19-9 C-reactive protein |
| title | Serum hsa-miR-22-3p, hsa-miR-885-5p, Lipase-to-Amylase Ratio, C-Reactive Protein, CA19-9, and Neutrophil-to-Lymphocyte Ratio as Prognostic Factors in Advanced Pancreatic Ductal Adenocarcinoma |
| title_full | Serum hsa-miR-22-3p, hsa-miR-885-5p, Lipase-to-Amylase Ratio, C-Reactive Protein, CA19-9, and Neutrophil-to-Lymphocyte Ratio as Prognostic Factors in Advanced Pancreatic Ductal Adenocarcinoma |
| title_fullStr | Serum hsa-miR-22-3p, hsa-miR-885-5p, Lipase-to-Amylase Ratio, C-Reactive Protein, CA19-9, and Neutrophil-to-Lymphocyte Ratio as Prognostic Factors in Advanced Pancreatic Ductal Adenocarcinoma |
| title_full_unstemmed | Serum hsa-miR-22-3p, hsa-miR-885-5p, Lipase-to-Amylase Ratio, C-Reactive Protein, CA19-9, and Neutrophil-to-Lymphocyte Ratio as Prognostic Factors in Advanced Pancreatic Ductal Adenocarcinoma |
| title_short | Serum hsa-miR-22-3p, hsa-miR-885-5p, Lipase-to-Amylase Ratio, C-Reactive Protein, CA19-9, and Neutrophil-to-Lymphocyte Ratio as Prognostic Factors in Advanced Pancreatic Ductal Adenocarcinoma |
| title_sort | serum hsa mir 22 3p hsa mir 885 5p lipase to amylase ratio c reactive protein ca19 9 and neutrophil to lymphocyte ratio as prognostic factors in advanced pancreatic ductal adenocarcinoma |
| topic | circulating miRNAs pancreatic ductal adenocarcinoma neutrophil–lymphocyte ratio lipase–amylase ratio CA19-9 C-reactive protein |
| url | https://www.mdpi.com/1467-3045/47/1/27 |
| work_keys_str_mv | AT jakubwnuk serumhsamir223phsamir8855plipasetoamylaseratiocreactiveproteinca199andneutrophiltolymphocyteratioasprognosticfactorsinadvancedpancreaticductaladenocarcinoma AT dorotahudy serumhsamir223phsamir8855plipasetoamylaseratiocreactiveproteinca199andneutrophiltolymphocyteratioasprognosticfactorsinadvancedpancreaticductaladenocarcinoma AT joannakatarzynastrzelczyk serumhsamir223phsamir8855plipasetoamylaseratiocreactiveproteinca199andneutrophiltolymphocyteratioasprognosticfactorsinadvancedpancreaticductaladenocarcinoma AT łukaszmichalecki serumhsamir223phsamir8855plipasetoamylaseratiocreactiveproteinca199andneutrophiltolymphocyteratioasprognosticfactorsinadvancedpancreaticductaladenocarcinoma AT kamildybek serumhsamir223phsamir8855plipasetoamylaseratiocreactiveproteinca199andneutrophiltolymphocyteratioasprognosticfactorsinadvancedpancreaticductaladenocarcinoma AT iwonagisterekgrocholska serumhsamir223phsamir8855plipasetoamylaseratiocreactiveproteinca199andneutrophiltolymphocyteratioasprognosticfactorsinadvancedpancreaticductaladenocarcinoma |